Riptide Bioscience
Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Their focus is on creating peptide-based therapeutics for cancer, inflammatory diseases, and microbial infections, especially those resistant to conventional treatments. The company advances both preclinical and early-stage clinical programs, collaborates with academic partners and government agencies, and holds patents for its engineered peptide design technologies.
Patents
What We Do
Peptide therapeutics designed for topical treatment of resistant bacterial and fungal infections, including diabetic wounds and candidiasis.
Engineered peptides targeting tumor-associated macrophages to modulate the tumor immune environment and inhibit tumor growth.
Peptide therapeutics with anti-inflammatory activity, aimed at diseases such as scleroderma, colitis, multiple sclerosis, and pulmonary fibrosis.
Development of peptides labeled with isotopes such as Gallium-68 for PET imaging of tumor-associated macrophages.
Battlefield Resuscitation
Infectious Diseases
Regenerative Medicine
Digital Health Technologies
Key People
President
Executive Vice President – Drug Design
Principal Scientist
Principal Scientist
News & Updates
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.
Publication in Antimicrobial Agents and Chemotherapy shows strong performance of peptide vs. standard treatments.
Results of research on broad-spectrum peptide for treating wound bacteria and biofilm published.
Dr. Jelani Zarif at Johns Hopkins was awarded a Cancer Moonshot Scholars R01 grant from NIH/NCI for research using peptide drug candidates to address metastatic prostate cancer.
Joint development with University of Alabama scientists demonstrated that radiolabeled peptides identify tumor-associated macrophages in murine cancer models.
Inhibition of pulmonary fibrosis demonstrated in animal models through administration of CD206-targeting peptides, work published in Cells.
A designed peptide showed efficacy against MRSA-infected diabetic wounds in a murine model. Results published in International Journal of Molecular Sciences.
Internationally recognized expert in systemic sclerosis joins board, collaborating on peptide therapeutics for scleroderma.
Publication in Science Translational Medicine establishes a new immune checkpoint involving CD206, with implications for cancer and fibrosis treatment.
Peer-reviewed article details efficacy of designed peptides for topical treatment of antibiotic-resistant acne vulgaris.
Study demonstrates efficacy of a designed peptide for recurrent vaginal fungal infections, appearing in Antimicrobial Agents and Chemotherapy.
Presentation of peptide therapeutics results for idiopathic pulmonary fibrosis at a major industry summit.
Broad-spectrum antimicrobial peptide for treating wound pathogens and biofilm described in Frontiers in Microbiology.
Preclinical results with anti-fibrotic peptides presented at the International Workshop on Scleroderma Research.
Awarded contract from NCI to evaluate a peptide in combination with radiotherapy as cancer treatment.
Awarded grant from NIDDK to develop peptide therapeutics for diabetic foot ulcers.
Defense Department Medical Research Programs highlighted Riptide's antimicrobial peptide research as an outstanding program.
Presented evaluation of antimicrobial peptides for combat-related wound infections to military research experts.
Keynote on macrophages in the tumor microenvironment at an international biotechnology and research conference.
Presentation on engineered peptide targeting CD206 in prostate and breast cancer models at AACR.
NIH grant to advance designed antimicrobial peptides for antibiotic-resistant acne.
Received Gold Award for Excellence at the Military Health Systems Research Symposium for antimicrobial peptide work.
Signed agreement to evaluate a peptide therapeutic in preclinical pancreatic cancer studies.
Received NIH Small Business Innovation Research grant to develop peptide therapeutics for bacterial keratitis.